Faping Li
Impact in
-
- Cancer, Lipids, and Metabolism
- Cancer, Hypoxia, and Metabolism
- Cancer-related molecular mechanisms research
Papers in
-
- Cancer, Lipids, and Metabolism 2
- Oncology 5
- Cancer Immunotherapy and Biomarkers 3
- Co-authors
- Honglan Zhou (12 shared papers)Hui Guo (5 shared papers)Yishu Wang (6 shared papers)Yu-Xiong Wang (8 shared papers)Bin Liu (6 shared papers)Bin Liu (4 shared papers)Yunkuo Li (6 shared papers)Yuchuan Hou (3 shared papers)
- Journals
- Frontiers in Pharmacology (3 papers)Biomedicine & Pharmacotherapy (3 papers)Frontiers in Oncology (2 papers)Frontiers in Endocrinology (2 papers)Clinical Nutrition (1 paper)
- Partner nations
- China
In The Last Decade
Faping Li
25 papers receiving 392 citations
Peers
Comparison fields: 5 of 66
- Drug Discovery 3
- Cancer Research 82
- Pharmaceutical Science 28
- Biomaterials 45
- Oncology 38
Countries citing papers authored by Faping Li
This map shows the geographic impact of Faping Li's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Faping Li with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Faping Li more than expected).
Fields of papers citing papers by Faping Li
This network shows the impact of papers produced by Faping Li. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Faping Li. The network helps show where Faping Li may publish in the future.
Co-authors
The 25 scholars most cited alongside Faping Li, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 25 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | 2023 | 75 | |
| 2 | 2020 | 56 | |
| 3 | 2019 | 41 | |
| 4 | 2023 | 34 | |
| 5 | 2020 | 29 | |
| 6 | 2020 | 27 | |
| 7 | 2022 | 20 | |
| 8 | 2023 | 18 | |
| 9 | 2019 | 13 | |
| 10 | 2019 | 11 | |
| 11 | 2023 | 11 | |
| 12 | 2023 | 10 | |
| 13 | 2022 | 9 | |
| 14 | 2024 | 9 | |
| 15 | 2020 | 7 | |
| 16 | 2020 | 7 | |
| 17 | 2025 | 6 | |
| 18 | 2024 | 5 | |
| 19 | 2021 | 4 | |
| 20 | 2023 | 2 |
About Faping Li
Faping Li is a scholar working on Cancer Research, Oncology, Toxicology, Molecular Biology and Biomaterials, having authored 25 papers that have together received 399 indexed citations. Recurring topics across this work include Cancer Immunotherapy and Biomarkers (3 papers), Pharmacovigilance and Adverse Drug Reactions (2 papers), Bladder and Urothelial Cancer Treatments (2 papers), Nanoparticle-Based Drug Delivery (2 papers), Cancer, Lipids, and Metabolism (2 papers), Renal cell carcinoma treatment (2 papers), Endoplasmic Reticulum Stress and Disease (1 paper) and Microtubule and mitosis dynamics (1 paper). The work is most often cited by research in Drug Discovery (3 citations), Cancer Research (82 citations), Pharmaceutical Science (28 citations), Biomaterials (45 citations) and Oncology (38 citations). Faping Li has collaborated with scholars based in China. Frequent co-authors include Honglan Zhou, Hui Guo, Yishu Wang, Yu-Xiong Wang, Bin Liu, Bin Liu, Yunkuo Li, Yuchuan Hou, Yanghe Zhang and Heping Qiu. Their work appears in journals such as Frontiers in Pharmacology, Biomedicine & Pharmacotherapy, Frontiers in Oncology, Frontiers in Endocrinology and Clinical Nutrition.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.